Obsidian Therapeutics
Cambridge
About Obsidian Therapeutics
Obsidian Therapeutics is a developer of a next-generation cell and gene therapies created to extend adoptive immunotherapy to every patient with cancer.The company's next-generation cell and gene therapies with pharmacologic operating systems provide exquisite control of protein activity in cells and create adoptive cell therapies with new functions that are under control of the treating physician using simple, safe, orally-active, marketed drugs, enabling patients to improve on the current generation of cell therapies.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 101 – 250
- Estimated revenue: $1K – $10K
- Total funding: $325.0M
- Funding stage: Late Stage Venture
- Last round: Series C (Apr 2024)
- Website: obsidiantx.com
- Phone: (781) 806-6245
Industries & Categories
Biotechnology, Health Care, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/obsidian-therapeutics-41592 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.